Efficacy of Octreotide on Blood and Iron Requirements in Patients With Anemia Due to Angiodysplasias
- Conditions
- AngiodysplasiaVascular MalformationsGastrointestinal HemorrhageAnemia
- Interventions
- Registration Number
- NCT02384122
- Lead Sponsor
- Radboud University Medical Center
- Brief Summary
The purpose of this study is to determine whether 40 mg octreotide long-acting release intramuscular every 28 days is effective in the treatment of patients with refractory anemia due to gastrointestinal angiodysplasias. We hypothesize that octreotide is effective in reducing the transfusion requirements (consisting of red blood cell transfusions and intravenous iron infusions) of patients with angiodysplasia-related anemia.
- Detailed Description
Rationale: Gastrointestinal angiodysplasias are a common source of intractable small bowel bleeding, especially in older patients. Endoscopic ablation of angiodysplasias has limited efficacy and rebleeding rates are substantial. Recurrent bleeding results in refractory anemia which is managed with blood transfusions and/or iron infusions. Transfusion dependency reduces quality of life and is associated with substantial cardiovascular morbidity and mortality. Small cohort studies suggest a beneficial effect of octreotide in bleeding angiodysplasias, but evidence from rigorous, well-controlled studies are lacking.
Objective: To assess the efficacy of octreotide in reducing the transfusion requirements (consisting of blood transfusions and iron infusions) of patients with refractory anemia due to gastrointestinal angiodysplasias despite endoscopic intervention.
Study design: Multicenter, randomized, open-label intervention study.
Study population: Patients aged 18 years or older with transfusion-dependent anemia due to endoscopically confirmed angiodysplasias. Transfusion units consist of iron infusions (of 500 milligrams \[mg\]) and red blood cell (RBC) transfusions. At least one endoscopic attempt to treat the angiodysplasias needs to be recorded unless contra-indications are present. Patients with liver cirrhosis Child-Pugh C or liver failure, uncontrolled diabetes mellitus (defined by a glycated hemoglobin \>64 mmol/mL), symptomatic cholecystolithiasis, and pregnant or nursing women, are regarded as ineligible because of the pharmacological profile of octreotide. Patients with hereditary hemorrhagic diseases or hematological disorders on active treatment, other alternative causes of gastrointestinal bleeding, presence of left ventricular assist devices, as well as patients with cancer under active treatment, and those with a life expectancy \<1 year are excluded from enrolment
Intervention: Patients will be randomized (1:1) into two groups. The intervention group receives 40 mg octreotide long-acting release (Sandostatin LAR) every 28 days for a total period of 52 weeks as an adjunct to standard of care. The control group receives standard of care along. The last follow-up visit is in week 60.
Main study parameters/endpoints: The primary endpoint is defined as the mean difference in blood (RBC transfusions per 500 ml or packed cells) and parenteral iron (IV iron infusions per 500 mg) requirements between the intervention and control group, corrected for baseline transfusion requirements and follow-up time.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 62
Not provided
- Liver cirrhosis Child-Pugh C, liver failure or diagnosed portal hypertension
- Previous treatment with octreotide for the same indication (refractory anemia due to angiodysplasias)
- Current thalidomide treatment which is effective (no transfusion dependency)
- Life expectancy < 1 year
- Left ventricular assist devices (LVAD's)
- Hereditary hemorrhagic diseases or hematological disorders with active treatment
- Pregnancy or nursing women
- Uncontrolled diabetes as defined by HbA1C >64 mmol/ml, despite adequate therapy
- Known hypersensitivity to somatostatin analogs
- Symptomatic cholecystolithiasis
- Systemic cancer under active treatment (chemotherapy or radiation therapy)
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Octreotide Octreotide Drug: Sandostatin LAR Sandostatin LAR 40 mg will be administered once every 4 weeks as a intramuscular injection
- Primary Outcome Measures
Name Time Method Difference in blood and parenteral iron requirements (transfusion units) Study year (52 weeks) The mean difference in blood (RBC transfusions per 500 ml or packed cells) and parenteral iron (IV iron infusions per 500 mg) requirements between the intervention and standard of care arm, corrected for baseline transfusion requirements and follow-up time.
- Secondary Outcome Measures
Name Time Method Difference in ferritin levels Study year (52 weeks) The mean difference in serum ferritin levels (ug/L) between both groups.
Use of concomitant care Study year (52 weeks) The proportion of patients in both groups that required concomitant care. Concomitant care consists of application of APC, discontinuation of antithrombotics, use of tranexamic acid, and starting octreotide in the control group.
Difference in endoscopic procedures Study year (52 weeks) The mean difference in endoscopic procedures between both groups.
Proportion with a good treatment response During the study year (52 weeks) compared to the year (52 weeks) before randomization The proportion of patients in both groups that experienced a ≥50% (defined as a good response) and 100% (defined as a full response) reduction in the number of transfusion units received during the study year compared to baseline
Difference in hemoglobin levels Study year (52 weeks) The mean difference in serum hemoglobin levels (mmol/L) between both groups.
Difference in quality of life Study year (52 weeks) The mean difference in quality of life between both groups. Quality of life is a patient-reported outcome measure (PROM), measured by the Short Form Health Survey (SF-36), which uses eight subdomains to evaluate physical- and mental health. SF-36 scores range from 0 (worst) to 100 (best).
Difference in serious adverse events Study year (52 weeks) The proportion of patients in both groups that experienced at least one serious adverse event (SAE).
Difference in mortality Study year (52 weeks) The proportion of patients in both groups that died during the study.
Difference in bleeding episodes Study year (52 weeks) The mean difference in bleeding episodes between both groups. A bleeding episode is defined as each non-contiguous episode in which hospital care is sought for anemia.
Difference in healthcare utilization Study year (52 weeks) The mean difference in healthcare utilization between both groups. Healthcare utilization consists of hospital admissions, ambulatory care, and emergency care.
Difference in fatigue levels Study year (52 weeks) The mean difference in fatigue levels between both groups. Fatigue is a patient-reported outcome measure (PROM), measured by the Multidimensional Fatigue Inventory (MFI-20), which covers five dimensions of fatigue affect and -tolerability. MFI-20 scores range from 20 (best) to 100 (worst).
Difference in adverse events Study year (52 weeks) The proportion of patients in both groups that experienced at least one adverse event (AE).
Trial Locations
- Locations (12)
Catharina Hospital
🇳🇱Eindhoven, Noord-Brabant, Netherlands
Gelre Hospital
🇳🇱Apeldoorn, Gelderland, Netherlands
Elisabeth-TweeSteden Hospital
🇳🇱Tilburg, Noord-Brabant, Netherlands
Radboud University Medical Center (Radboudumc)
🇳🇱Nijmegen, Gelderland, Netherlands
Jeroen Bosch Hospital
🇳🇱's-Hertogenbosch, Noord-Brabant, Netherlands
St. Antonius Hospital
🇳🇱Nieuwegein, Utrecht, Netherlands
Tjongerschans Hospital
🇳🇱Heerenveen, Netherlands
Reinier de Graaf Gasthuis
🇳🇱Delft, Zuid-Holland, Netherlands
Rijnstate Hospital
🇳🇱Arnhem, Netherlands
Maasstad Hospital
🇳🇱Rotterdam, Netherlands
Bernhoven Hospital
🇳🇱Uden, Netherlands
University Medical Center Groningen (UMCG)
🇳🇱Groningen, Netherlands